Gynecology

  HRT: WHERE WE CAME FROM, WHERE ARE WE GOING?
Chairpersons Alesandra Graziottin, Italy
Santiago Palacios, Spain
Lights and shadows in WHI: A never ending nightmare!
Andrea Genazzani, Italy
HRT for primary prevention?
John Stevenson, UK
  Clinical data and national/international guidelines
Nick Panay, UK
HRT PRESCRIBING: MAKING THE SCIENCE APPLICABLE IN THE REAL-WORLD
Capsule The development of alternatives to HRT to treat vaginal atrophy was accelerated due to the sharp drop in HRT following WHI.
HRT Treatment – Are they all the same
Nick Panay, UK
Practical approach to HRT treatment
Louise Newson, UK
  Debate: Vaginal laser: Erbium or Co2 – which has superior data?
Erbium:
Co2:
TBA
HRT in cancer survivors
Pierluigi Benedetti Panici, Italy
Results of high dose estetrol (E4) treatment in women with advanced breast cancer
Carole Verhoeven, Netherlands
  Can HRT be individualized to reduce the incidence of breast cancer?
  Special countercurrent lecture:
Estrogens can protect against breast cancer
Herjan Coelingh Bennink,
 Netherlands
  PREMATURE OVARIAN INSUFFICIENCY- POI: ADVANCES IN DIAGNOSIS AND MANAGEMENT      
 Capsule Can better understanding help in providing treatment to this frustrating condition?
 Chairperson Andrea Genazzani, Italy
  Can we reliably predict POI using AMH?
  100,000 genomes project to unravel etiology of early POI
Brianna Cloke, UK
Global POI registry to optimize management
Nick Panay, UK
ESHRE POI guidelines: Where to next?
Lisa Webber, UK
  SLS: THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS: UPDATES ON THE STATE OF THE ART OF MINIMALLY INVASIVE SURGERY TO PRESERVE FERTILITY
The current status of Robotic Surgery in the field of Infertility
Mona Orady, USA
Surgical management of multi-organ endometriosis and pregnancy outcomes
Theirs Raymondo Soares, USA
Radio-frequency ablation: Applications for the preservation of the fibroid uterus
Jessica Ybanez-Morano, USA
Endometriosis in adolescence
George Creatsas, Greece
GENERATING AN HPV DIAGNOSIS IN A SCREENING EVENT
Capsule Screening programs need to decide on the technologies employed and usually rely on labs decisions. However, clinicians would benefit from better understanding the subtleties of HPV diagnostics.
Moderator Xavier Bosch, Spain
Chairpersons Jorma PaavonenFinland
Mario Poljak, Slovenia
Questions
  • Sampling and self-sampling
  • HPV tests interferences: Blood / Infections
  • HPV testing: Sensitivity and specificity of the test
  • The value of type specific testing: Cocktail vs. some types vs. all types
  • Multiple HPV infections: What do they convey as a predictor of risk?
  • Co-testing: The obvious and the uncertain
  • Other
  HPV VACCINES: LIGHTS AND SHADOWS  
Capsule In Europe, as well as in some developing countries, non-scientific claims of serious adverse events following vaccination are challenging public programs and undermining vaccine confidence.
Moderator Xavier Bosch, Spain
Participants Elmar Joura, Austria
Jorma Paavonen, Finland
  Questions:
What is vaccine hesitancy?
Vaccine safety: The weight of the evidence
The creation and spreading of a rumor: Impact on public programs
mandatory vaccination
How to confront vaccine hesitancy and anti-vaccine positions
Other
PREMATURE OVARIAN FAILURE
Fertility preservation – women with a family history of POI should be offered oocyte cryopreservation.
  Debate: Should androgens be routinely offered to optimize quality of life in menopause?
For: Alessandra Graziottin, Italy
Against: Johannes Bitzer, Switzerland
NEW FRONTIERS IN MENOPAUSE RESEARCH: THE YOUNG PIONEERS
Women’s reproductive health and its relation to diabetes and cardiovascular health
Cardiovascular impact of androgens in women
Does the type of HRT matter in POI?
Non-instrumental screening method for low BMD in women with secondary amenorrhea

*The scientific program is subject to change.